Actinium Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Actinium Pharmaceuticals Inc.
Vanguard Total Stock Market Index Fund
1,543,137
1.4%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
751,840
0.68%
22,778
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
393,751
0.36%
120,052
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
140,200
0.13%
0
0.02%
12/31/2017
APO Medical Opportunities
112,568
0.1%
112,568
0.01%
03/31/2018
Vanguard Institutional Total Stock Market Index Fund
106,660
0.1%
0
0%
07/31/2018
APO Medical Opportunities Institutionell
80,000
0.07%
80,000
0.03%
06/29/2018
Fidelity Spartan Total Market Index Fund
38,656
0.04%
0
0%
07/31/2018
Vanguard Balanced Index Fund
22,130
0.02%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
18,902
0.02%
0
0%
09/06/2018
| Address |
275 Madison Avenue
New York New York 10016
United States
|
|
Employees
|
- |
| Website |
http://www.actiniumpharmaceuticals.com |
| Updated |
07/08/2019 |
| Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. |
